Joanne De Jesus

TL;DR: RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life, and the suggestion of a possible benefit with respect to other end-point events involving RSv-associated respiratory disease in infants warrants further study.

TL;DR: Intent to vaccinate infants aged 6-11 months in four middle income countries was tied primarily to knowledge of the vaccine and perceptions of vaccine safety and effectiveness.

TL;DR: In this article, a prognostic clinical prediction tool was developed to assist community healthcare providers to identify febrile children who might benefit from referral or admission for facility-based medical care.

TL;DR: The IRIS promises to expand the knowledge of the frequency, clinical features, and antibody profiles of serious influenza and RSV disease among infants aged <1 year, quantify the proportion of infections that may be missed by traditional surveillance, and inform decisions about the potential value of existing and new vaccines and other prevention and treatment strategies.

TL;DR: A novel assessment methodology based on training local field workers, advances in audiometric testing equipment and cloud-based technology overcomes challenges of distant large-scale population otologic/audiometric assessment.